- Previous Close
11,390.00 - Open
11,400.00 - Bid 10,980.00 x --
- Ask 11,080.00 x --
- Day's Range
10,950.00 - 11,450.00 - 52 Week Range
10,560.00 - 20,500.00 - Volume
95,236 - Avg. Volume
86,822 - Market Cap (intraday)
305.86B - Beta (5Y Monthly) 0.91
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Dec 27, 2019
- 1y Target Est
25,000.00
Ildong Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company offers active lactic acid bacterial and anti-diarrheal agents, antibiotics, antifungal and antiviral products, anti-histamine drugs, antineoplastic agents, and NSAIDs and analgesics, as well as vitamins, minerals, and nutrients; and drugs for blood circulation, cardiovascular and central nervous system, dental, endocrine and metabolic system, gastrointestinal system, respiratory system, topical preparation, and urogenital system applications. It also provides raw material drugs; health foods and foods; cosmetics; medical devices for scar treatment; and other drugs for treating thick wounds, osteoarthritis, periarthritis of shoulder, and artificial tears, as well as feminine cleanser products. In addition, the company manages licenses and provides contract manufacturing services. It also exports its products to approximately 20 countries worldwide. Ildong Pharmaceutical Co., Ltd. a strategic collaboration with Evotec SE to accelerate the development of various Ildong's proprietary projects through access to Evotec's INDiGO platform. The company was founded in 1941 and is headquartered in Seoul, South Korea.
www.ildong.com1,020
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 249420.KS
View MorePerformance Overview: 249420.KS
Trailing total returns as of 12/20/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 249420.KS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 249420.KS
View MoreValuation Measures
Market Cap
305.86B
Enterprise Value
439.32B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.50
Price/Book (mrq)
1.95
Enterprise Value/Revenue
0.72
Enterprise Value/EBITDA
17.95
Financial Highlights
Profitability and Income Statement
Profit Margin
-8.06%
Return on Assets (ttm)
-1.92%
Return on Equity (ttm)
-30.55%
Revenue (ttm)
603.86B
Net Income Avi to Common (ttm)
-48.68B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
70.91B
Total Debt/Equity (mrq)
126.49%
Levered Free Cash Flow (ttm)
12.96B